Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Despite the increasing number of treatment options available for multiple myeloma, relapse is still inevitable and there remains a critical unmet need for treatments for patients with late-stage, highly refractory disease. In this review, we discuss currently approved treatment options for heavily p...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical lymphoma, myeloma and leukemia Vol. 22; no. 7; pp. 460 - 473
Main Authors:	Dimopoulos, Meletios-Athanasios, Richardson, Paul, Lonial, Sagar
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.07.2022
Subjects:	Anti-CD38 antibody Elotuzumab Heavily pretreated Immunomodulatory drugs Monoclonal antibodies Multiple myeloma Pomalidomide Proteasome inhibitors Relapsed/refractory Immunomodulatory drugs Multiple myeloma Heavily pretreated Monoclonal antibodies Anti-CD38 antibody Pomalidomide Relapsed/refractory Proteasome inhibitors Elotuzumab
ISSN:	2152-2650, 2152-2669, 2152-2669
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!